JUL 12, 2016 07:30 AM PDT

Introduction to the PATHFAST, a Cardiac Biomarker Analyzer Specializing in Precise and Accurate Results Unaffected by Hemolysis

SPONSORED BY: Vert Clinical Leader
Speakers

Abstract:

PATHFAST is a small, benchtop cardiac marker analyzer with industry-leading precision designed for ED and stat labs. PATHFAST is the only point-of-care cardiac biomarker analyzer in the market with a 5.1% CV for Troponin I at the 99th percentile cutoff. With the flexibility to run whole blood or plasma samples, PATHFAST allows for up to six simultaneous tests in under 17 minutes. The test menu includes Troponin, CK-MB, NTproBNP, D-Dimer, hsCRP and Myoglobin, and test results are unaffected by hemolysis, providing accurate, fast results – helping clinicians diagnose patients more effectively and efficiently.
 
Our goal is to not just to provide the best whole blood cardiac biomarker analyzer in the industry, but to improve the quality of patient care while simultaneously reducing costs.
 
PATHFAST is manufactured in Japan, from quality components, and under the strictest quality control standards.
 


Show Resources
You May Also Like
JUN 26, 2018 06:00 AM PDT
C.E. CREDITS
JUN 26, 2018 06:00 AM PDT
Date: June 26, 2018Time: 6:00 a.m. PDT, 9:00 a.m. EDT, 1500 CEST Today’s hematology analyzers employ various methods for enumerating platelets. These methods include: e...
MAY 03, 2018 08:00 AM PDT
C.E. CREDITS
MAY 03, 2018 08:00 AM PDT
DATE:  May 3rd, 2018TIME:   8:00 AM PDT, 11:00 AM EDTIntestinal inflammation is a hallmark of the inflammatory bowel diseases (IBD), including ulcerative colitis and Cr...
MAY 24, 2018 09:30 AM PDT
C.E. CREDITS
MAY 24, 2018 09:30 AM PDT
DATE: May 24, 2018 TIME: 9:30PM PDT The current gold standard in in vitro pre-clinical cancer treatment screening remain cell lines,...
JUN 20, 2018 10:00 AM EDT
C.E. CREDITS
JUN 20, 2018 10:00 AM EDT
DATE: June 20, 2018TIME: 07:00AM PDT, 10:00AM EDTIntroducing GE’s New Lyo-StableTM service. Sepsis is one of the top challenges facing hospitals in terms of clinical outcomes...
AUG 15, 2018 08:00 AM PDT
C.E. CREDITS
AUG 15, 2018 08:00 AM PDT
DATE: August 15, 2018TIME: 08:00AM PDT, 11:00AM EDTThe failure of current chemotherapeutic strategies in the fight against cancer can be largely attributed to the occurrence of drug res...
MAY 24, 2018 09:00 AM PDT
C.E. CREDITS
MAY 24, 2018 09:00 AM PDT
Recent advances in immuno-oncology research has proven the critical role of immune cells in cancer therapy. Deep understanding of the interaction and phenotype of immune and tumor cells withi...
Loading Comments...